title: Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene.
abstract: OBJECTIVE
  To observe the effect of octreotide on apoptosis rate of human pancreatic cancer cells PC-3 after transfected with somatostatin receptor type 2 (SST2) gene.
  
  
  METHODS
  SST2 plasmid was transfected into PC-3 cells by liposome. Result of transfection was detected by immunocytochemical staining and Western blotting. Apoptosis rates of PC-3 cells under different dosages of octreotide were measured by MTT assay and flow cytometry (FCM).
  
  
  RESULTS
  Apoptosis rate caused by octreotide of transfected PC-3 cells was 7.56+/-1.06% at the dosage of 0.20 microg/mL, 9.25+/-1.73% at the dosage of 0.40 microg/mL and 14.18+/-2.71% at the dosage of 0.80 microg/mL. Apoptosis rate caused by octreotide of non-transfected PC-3 cells was 5.76+/-0.75% at the dosage of 0.20 microg/mL, 6.69+/-0.80% at the dosage of 0.40 microg/mL and 7.26+/-1.28% at the dosage of 0.80 microg/mL. Transfected PC-3 cells growth inhibition rate caused by octreotide was 9.36+/-1.34% at the dosage of 0.20 microg/mL, 12.03+/-1.44% at the dosage of 0.40 microg/mL and 20.23+/-4.21% at the dosage of 0.80 microg/mL. Non-transfected PC-3 cells growth inhibition rate caused by octreotide was 6.44+/-0.66% at the dosage of 0.20 microg/mL, 7.65+/-0.88% at the dosage of 0.40 microg/mL and 9.29+/-1.32% at the dosage of 0.80 microg/mL. We found that octreotide caused higher apoptosis rate and inhibition rate in transfected groups than in non-transfected groups (P<0.05) at the tested dosages (0.20, 0.40 and 0.80 microg/mL).
  
  
  CONCLUSIONS
  Deficiency of SST2 was probably the major reason why octreotide had little effect on PC-3 cells. Transfecting SST2 gene could strengthen the ability of octreotide of killing PC-3 cells. It provided an experimental evidence for using both octreotide and transfection with SST2 gene on clinical treatment of pancreatic cancer.
authors.affiliation: Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
authors.forename: Zheng-Ren
authors.initials: ZR
authors.lastname: Liu
authors.forename: Ren-Yi
authors.initials: RY
authors.lastname: Qin
authors.forename: Gao-Song
authors.initials: GS
authors.lastname: Wu
authors.forename: Qing
authors.initials: Q
authors.lastname: Chang
authors.forename: Da-Yu
authors.initials: DY
authors.lastname: Wang
authors.forename: Sheng-Quan
authors.initials: SQ
authors.lastname: Zou
authors.forename: Fa-Zu
authors.initials: FZ
authors.lastname: Qiu
mesh_terms: D017209:Apoptosis; D045744:Cell Line, Tumor; D006801:Humans; D015282:Octreotide / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000503:physiopathology*; D017481:Receptors, Somatostatin / Q000235:genetics*; D014162:Transfection
chemical_list: D017481:Receptors, Somatostatin; C093733:somatostatin receptor 2; D015282:Octreotide